ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$0.73 USD
-0.04 (-4.58%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.70 -0.03 (-4.10%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
IPA 0.73 -0.04(-4.58%)
Will IPA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IPA
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
IPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 7th
New Strong Buy Stocks for February 5th
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
Other News for IPA
Buy Rating Affirmed: ImmunoPrecise’s Strong Financials and AI Advancements Signal Growth Potential
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2024 Earnings Call Transcript
ImmunoPrecise reports Q4 results
ImmunoPrecise Antibodies reports Q4 revenue C$6.46M vs. C$5.62M last year